Raymond James Financial Services Advisors’s Exact Sciences EXAS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $888K | Buy |
13,029
+458
| +4% | +$25.8K | ﹤0.01% | 2241 |
|
|
2024
Q2 | $531K | Sell |
12,571
-6,066
| -33% | -$334K | ﹤0.01% | 2492 |
|
|
2024
Q1 | $1.29M | Buy |
18,637
+778
| +4% | +$49.2K | ﹤0.01% | 1913 |
|
|
2023
Q4 | $1.32M | Sell |
17,859
-541
| -3% | -$35.5K | ﹤0.01% | 1816 |
|
|
2023
Q3 | $1.26M | Sell |
18,400
-9,284
| -34% | -$788K | ﹤0.01% | 1777 |
|
|
2023
Q2 | $2.6M | Sell |
27,684
-22,428
| -45% | -$1.75M | ﹤0.01% | 1374 |
|
|
2023
Q1 | $3.4M | Sell |
50,112
-35,164
| -41% | -$2.26M | 0.01% | 1187 |
|
|
2022
Q4 | $4.22M | Buy |
85,276
+23,818
| +39% | +$973K | 0.01% | 1056 |
|
|
2022
Q3 | $2M | Sell |
61,458
-1,912
| -3% | -$78.8K | ﹤0.01% | 1425 |
|
|
2022
Q2 | $2.5M | Buy |
63,370
+9,907
| +19% | +$530K | 0.01% | 1323 |
|
|
2022
Q1 | $3.74M | Buy |
53,463
+5,712
| +12% | +$418K | 0.01% | 1154 |
|
|
2021
Q4 | $3.72M | Sell |
47,751
-14,312
| -23% | -$1.26M | 0.01% | 1165 |
|
|
2021
Q3 | $5.92M | Buy |
62,063
+3,756
| +6% | +$397K | 0.01% | 882 |
|
|
2021
Q2 | $7.25M | Buy |
58,307
+14,486
| +33% | +$1.73M | 0.01% | 807 |
|
|
2021
Q1 | $5.78M | Sell |
43,821
-436
| -1% | -$59.7K | 0.01% | 842 |
|
|
2020
Q4 | $5.86M | Sell |
44,257
-3,332
| -7% | -$403K | 0.01% | 768 |
|
|
2020
Q3 | $4.85M | Buy |
47,589
+10,142
| +27% | +$876K | 0.01% | 771 |
|
|
2020
Q2 | $3.26M | Sell |
37,447
-673
| -2% | -$53.8K | 0.01% | 889 |
|
|
2020
Q1 | $2.21M | Sell |
38,120
-285
| -0.7% | -$23.1K | 0.01% | 843 |
|
|
2019
Q4 | $3.55M | Buy |
38,405
+1,966
| +5% | +$173K | 0.01% | 864 |
|
|
2019
Q3 | $3.29M | Sell |
36,439
-611
| -2% | -$69.6K | 0.01% | 861 |
|
|
2019
Q2 | $4.37M | Sell |
37,050
-1,985
| -5% | -$200K | 0.02% | 731 |
|
|
2019
Q1 | $3.38M | Buy |
39,035
+542
| +1% | +$46.1K | 0.01% | 807 |
|
|
2018
Q4 | $2.43M | Buy |
38,493
+7,531
| +24% | +$517K | 0.01% | 804 |
|
|
2018
Q3 | $2.44M | Sell |
30,962
-250
| -0.8% | -$16.3K | 0.01% | 952 |
|
|
2018
Q2 | $1.87M | Buy |
31,212
+3,568
| +13% | +$192K | 0.01% | 1058 |
|
|
2018
Q1 | $1.11M | Sell |
27,644
-14,078
| -34% | -$687K | 0.01% | 1241 |
|
|
2017
Q4 | $2.19M | Buy |
41,722
+3,187
| +8% | +$170K | 0.01% | 866 |
|
|
2017
Q3 | $1.82M | Buy |
38,535
+19,014
| +97% | +$765K | 0.01% | 962 |
|
|
2017
Q2 | $690K | Buy |
19,521
+7,921
| +68% | +$244K | ﹤0.01% | 1494 |
|
|
2017
Q1 | $274K | Sell |
11,600
-2,800
| -19% | -$55.5K | ﹤0.01% | 1951 |
|
|
2016
Q4 | $192K | Buy |
+14,400
| New | +$232K | ﹤0.01% | 2078 |
|
|
2016
Q3 | – | Sell |
-15,700
| Closed | -$192K | – | 2328 |
|
|
2016
Q2 | $192K | Buy |
+15,700
| New | +$118K | ﹤0.01% | 1985 |
|
|
2015
Q4 | – | Sell |
-138,122
| Closed | -$2.48M | – | 1597 |
|
|
2015
Q3 | $2.48M | Buy |
+138,122
| New | +$3.17M | 0.04% | 454 |
|
Other funds holding EXAS
Raymond James Financial Services Advisors's EXAS Position: Q3 2024 in Review
Raymond James Financial Services Advisors increased its Exact Sciences (EXAS) stake by 3.6% in Q3 2024, buying an estimated $25.8K and bringing the position to 13,029 shares worth $888K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.
Raymond James Financial Services Advisors first reported a position in EXAS in Q3 2015 and has held it in 34 quarters since. The position peaked at $7.25M in Q2 2021. 600 funds tracked by Wall St. Rank hold EXAS as of Q3 2024.
- Raymond James Financial Services Advisors held 13,029 shares of Exact Sciences worth $888K as of Q3 2024.
- Raymond James Financial Services Advisors bought 458 Exact Sciences shares in Q3 2024, an estimated $25.8K.
- Exact Sciences made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #2241 holding.
- Raymond James Financial Services Advisors first reported a position in Exact Sciences in Q3 2015 and has held it in 34 quarters since.
- Raymond James Financial Services Advisors's Exact Sciences position peaked at $7.25M in Q2 2021.
- 600 funds tracked by Wall St. Rank held Exact Sciences as of Q3 2024.
Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.